Sanofi
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine
Recursion and Exscientia complete AI-based drug development merger, creating a trans-Atlantic powerhouse with over 30 clinical and preclinical programs. The combined company, headquartered in Salt Lake City, focuses on oncology and rare diseases, with REC-617 (CDK7 inhibitor) and REC-994 (CCM treatment) as key candidates. The merger aims to generate $100 million in annual savings through operational synergies, including job cuts, and expects to receive over $20 billion in additional milestone payments from partnerships with Roche, Sanofi, Bayer, and others.
Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034
The hidradenitis suppurativa market is projected to grow at a CAGR of 12.4% by 2034, driven by increased awareness, treatment access, biologic therapy approvals, and a robust pipeline. The market size in the 7MM was USD 1.4 billion in 2023, with approximately 6.2 million prevalent cases. Key companies and treatments include Incyte Corporation, AbbVie, MoonLake Immunotherapeutics, and therapies like Povorcitinib, RINVOQ, Lutikizumab, and Sonelokimab. Regulatory milestones and clinical trials are advancing, with potential market shifts expected from emerging therapies.
BioNJ Unveils "Time Off for Clinical Trials" Initiative
BioNJ launches 'Time Off for Clinical Trials' initiative, encouraging member companies to offer paid time off for employees to participate in clinical trials. Amicus Therapeutics, Bristol Myers Squibb, Genmab, PsychoGenics, PTC Therapeutics, and Sanofi are among the initial companies committed to implementing this policy.
Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential
TD Cowen maintains Buy rating on Vir Biotechnology, citing promising data for HBV and HDV treatments. Eleb+tobe combination therapy for HDV could start pivotal program in 2025. Vir's negative enterprise value presents potential for stock outperformance. Recent progress includes positive EMA opinions for orphan drug designations and a licensing agreement with Sanofi. Despite financial challenges, Vir's cash reserves and pipeline advancements suggest a bullish outlook.
FDA approves Bimzelx for adults with moderate to severe hidradenitis suppurativa
FDA approves Bimzelx, the first interleukin-17F and -17A inhibitor, for moderate to severe hidradenitis suppurativa in adults, based on BE HEARD trials results.
A Rising EU Antitrust Enforcement Tide: 'Exclusionary Disparagement' of Pharma Rivals
The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.
BioNJ Unveils 'Time Off for Clinical Trials' Initiative
BioNJ launches 'Time Off for Clinical Trials' initiative, encouraging member companies to offer paid time off for employees to participate in clinical trials. Amicus Therapeutics, Bristol Myers Squibb, Genmab, PsychoGenics, PTC Therapeutics, and Sanofi are among the first to commit. The initiative aims to remove barriers to participation in clinical trials, particularly for hourly workers and underrepresented populations.
Pfizer bags EU okay for haemophilia drug Hympavzi
Pfizer's Hympavzi is the first once-weekly subcutaneous treatment for severe haemophilia B in the EU, approved for adults and adolescents aged 12 and over without inhibitors. It offers bleed prevention and simplified administration via a pre-filled pen, reducing annualised bleeding rate by 35% in a phase 3 study. Hympavzi competes with Roche's Hemlibra and Sanofi's Altuviiio, with haemophilia B being its primary market.
Navigating The Shifting Sands Of Biotechnology Patenting (Video)
Recent landmark cases, EPO's G2/21 and U.S. Supreme Court's Amgen v. Sanofi, have reshaped biotechnology patenting by emphasizing sufficiency of disclosure and enablement. G2/21 allows post-filing evidence if credibly disclosed, while Amgen v. Sanofi requires comprehensive disclosure for broad claims. Practitioners now favor data-heavy applications and layered claims to balance breadth and sufficiency, with increased focus on freedom-to-operate and competitor monitoring.
© Copyright 2024. All Rights Reserved by MedPath